What Is Foundayo?

1. What Is Foundayo?

Foundayo is the brand name for orforglipron tablets. The FDA announced on April 1, 2026, that it approved Foundayo for use with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long-term in adults with obesity or overweight and at least one weight-related comorbid condition (FDA, 2026).

The active ingredient is orforglipron. The product form is an oral tablet. It is classified as a GLP-1 receptor agonist.

The FDA’s 2026 novel drug approvals page lists Foundayo under the active ingredient orforglipron, with an approval date of April 1, 2026 (FDA novel approvals, 2026).

For the active-ingredient companion page, see What Is Orforglipron?.

2. What Is Orforglipron?

Orforglipron is the active ingredient in Foundayo. DailyMed identifies Foundayo as orforglipron tablets for oral use and describes it as a GLP-1 receptor agonist (DailyMed, 2026).

Peer-reviewed clinical literature describes orforglipron as an oral small-molecule, non-peptide GLP-1 receptor agonist developed for type 2 diabetes and weight management (PubMed, 2025; PubMed, 2023).

This distinction matters because oral semaglutide is a peptide GLP-1 medicine formulated for oral absorption, whereas orforglipron is a non-peptide molecule. “Oral GLP-1” now encompasses different types of active ingredients.

For broader class information, see What Is a GLP-1?.

3. What Did FDA Approve?

The FDA’s approval announcement states Foundayo is approved in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long-term in specified adults (FDA, 2026).

The NDA approval letter identifies NDA 220934 for Foundayo (orforglipron) tablets with the same high-level indication (FDA approval letter, 2026). DailyMed provides the full prescribing information, warnings, limitations, and current label details.

4. Why Is Foundayo Different From Oral Semaglutide?

Foundayo is different from oral semaglutide because its active ingredient is orforglipron.

Oral semaglutide is available in the U.S. under names such as Rybelsus and Ozempic tablets. While the phrase “GLP-1 pill” is sometimes used to describe all of these medications, they involve different molecules, manufacturers, and regulatory histories.

For oral semaglutide background, see What Is Rybelsus?, What Is Ozempic?, and What Is Semaglutide?.

5. How Is Foundayo Different From Injectable GLP-1 Products?

Foundayo is an oral tablet, while many well-known GLP-1 products are injections. Injectable GLP-1 medications typically utilize pens, vials, or syringes for subcutaneous administration. Foundayo provides GLP-1 receptor agonist activity in a tablet format.

For a more general class explainer, see What Is a GLP-1?.

6. Why the April 2026 Approval Matters

The April 1, 2026, FDA announcement is notable because Foundayo was approved as a new molecular entity through the Commissioner’s National Priority Voucher pilot program. The FDA described the action as the first new molecular entity approved under that program, with the review completed prior to the original PDUFA date. This approval officially introduced orforglipron into the U.S. oral GLP-1 market.

7. What Foundayo Is Not

Foundayo is not oral Ozempic, Rybelsus, or a generic name for all GLP-1 pills. It is not an injectable semaglutide or tirzepatide product.

• Foundayo: Orforglipron tablets.
• Rybelsus: Oral semaglutide tablets.
• Ozempic tablets: Ozempic-branded oral semaglutide.
• Wegovy: Injectable semaglutide labeled for weight management.
• Injectable GLP-1: A product delivery form, not a specific active ingredient.

8. What Is Foundayo FAQ

• What is Foundayo in simple terms?

  Foundayo is the brand name for orforglipron tablets. The FDA approved Foundayo on April 1, 2026, as an oral GLP-1 receptor agonist used with a reduced-calorie diet and increased physical activity for long-term weight reduction in specified adults.

• Is Foundayo the same as orforglipron?

  Yes. Foundayo is the brand name and orforglipron is the active ingredient. FDA approval documents identify the product as Foundayo (orforglipron) tablets under NDA 220934.

• Is Foundayo the same as Rybelsus or an Ozempic pill?

  No. Foundayo contains orforglipron and is a Lilly oral GLP-1 tablet labeled for weight-management. Rybelsus and Ozempic tablets contain semaglutide and have different brand and label contexts.

• Is Foundayo an injectable GLP-1 medicine?

  No. FDA and DailyMed materials describe Foundayo as tablets for oral use. Injectable GLP-1 products have different product forms, labels, and handling details.

9. Sources